Ignite Creation Date:
2025-12-24 @ 5:55 PM
Ignite Modification Date:
2025-12-28 @ 4:58 AM
Study NCT ID:
NCT05013268
Status:
UNKNOWN
Last Update Posted:
2021-08-24
First Post:
2021-08-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical Carcinoma
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'C000707970', 'term': 'tislelizumab'}, {'id': 'D017239', 'term': 'Paclitaxel'}, {'id': 'D000077143', 'term': 'Docetaxel'}], 'ancestors': [{'id': 'D043823', 'term': 'Taxoids'}, {'id': 'D043822', 'term': 'Cyclodecanes'}, {'id': 'D003516', 'term': 'Cycloparaffins'}, {'id': 'D006840', 'term': 'Hydrocarbons, Alicyclic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D004224', 'term': 'Diterpenes'}, {'id': 'D013729', 'term': 'Terpenes'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SEQUENTIAL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 15}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2021-09', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2021-08', 'completionDateStruct': {'date': '2022-12', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2021-08-18', 'studyFirstSubmitDate': '2021-08-17', 'studyFirstSubmitQcDate': '2021-08-18', 'lastUpdatePostDateStruct': {'date': '2021-08-24', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2021-08-19', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-06', 'type': 'ESTIMATED'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Biomarkers analysis', 'timeFrame': 'Up to approximately 12 months', 'description': 'The association between biomarkers expression (eg. PD-L1 CPS) in primary tumor and efficacy.'}], 'primaryOutcomes': [{'measure': 'Major pathological response (MPR) rate', 'timeFrame': 'Up to approximately 8 weeks following completion of neoadjuvant treatment', 'description': 'Major pathological response rate is defined as the percentage of participants having ≤10% viable tumor cells in the resected primary tumor and all resected lymph nodes following completion of neoadjuvant therapy.'}], 'secondaryOutcomes': [{'measure': 'Pathological Complete Response (pCR) Rate', 'timeFrame': 'Up to approximately 8 weeks following completion of neoadjuvant treatment', 'description': 'rate is defined as the percentage of participants having an absence of residual invasive cancer in resected lung specimens and lymph nodes following completion of neoadjuvant therapy.'}, {'measure': 'Objective response rate (ORR)', 'timeFrame': 'Up to 30 days after last completion of neoadjuvant treatment', 'description': 'Objective Response Rate is defined as the percentage of patients with a documented complete response or partial response (CR + PR) based on RECIST v1.1.'}, {'measure': 'Relapse free survival (RFS)', 'timeFrame': 'Up to approximately 36 months', 'description': 'Relapse free survival is defined as the time from surgery to first local, regional, or distant tumor recurrence or metastasis, or deaths.'}, {'measure': 'Disease free survival (DFS)', 'timeFrame': 'Up to approximately 36 months', 'description': 'disease-free survival (DFS) is defined as surgery until documented disease recurrence or death from any cause in all patients (ITT population) who undergo surgery'}, {'measure': 'Adverse Events', 'timeFrame': 'Up to approximately 12 months', 'description': 'All patients who have received at least one dose of treatment will be included in the safety analysis. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0'}, {'measure': 'Overall survival (OS)', 'timeFrame': 'Up to approximately 60 months', 'description': 'Overall survival is defined as the time from signing ICF until death from any cause.'}]}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Cervical Squamous Cell Carcinoma']}, 'descriptionModule': {'briefSummary': 'The goal of this clinical trail is to investigate the efficacy and safety of PD-1 antibody Tislelizumab plus TP regimen (taxane combined with platinum) as neoadjuvant therapy for patients diagnosed as local advanced cervical carcinoma (FIGO staging IB2-IIB).', 'detailedDescription': 'This phase I study is being conducted to establish efficacy and safety of Tislelizumab plus TP regimen (taxane combined with platinum) as neoadjuvant therapy for patients diagnosed as local advanced cervical carcinoma (FIGO staging IB2-IIB).\n\nAll enrolled patients will receive same intervention. Treatment naïve patients who are diagnosed as local advanced cervical squamous cell carcinoma will receive Tislelizumab plus TP regimen before surgery for 3 cycles. After treatment, radiographic evaluation will be performed to assess clinical efficacy. Patients who have objective response will undergo radical surgery. Patients who are disease stable or progression will undergo radical chemoradiotherapy. The primary endpoint is major pathological response rate (MPR).'}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Histologically confirmed cervical squamous cell carcinoma.\n2. Clinical staging FIGO IB2-IIB, treatment naive.\n3. Female patients aged≥18 years.\n4. ECOG performance status 0 or 1, expected lifetime≥3 months.\n5. Adequate organ function: Absolute neutrophil count (ANC) ≥1.5x109/L, White blood count ≥3.5x109/L, Platelets ≥75x109/L, Hemoglobin (Hb) ≥90g/L, ALT/AST ≤2.5x ULN, Serum bilirubin ≤1.5x ULN, Serum creatinine ≤1.5x ULN.\n6. HBV infected patients (inactive/asymptomatic carrier, chronic or active) with HBV DNA\\<500IU/ml (or 2500 copies/ml).\n7. Pregnancy test of female patients with fertile activity should be negative within 7 days before enrollment. Patients should keep contraception during treatment.\n8. Willingness and ability to comply with the protocol for the duration of the study including scheduled visits, examinations, investigations and treatment plans with informed consent form.\n\nExclusion Criteria:\n\n1. Pregnancy or children bearing potential.\n2. brain or meningeal metastasis.\n3. With second primary malignant diseases.\n4. With uncontrolled auto-immune diseases, interstitial pneumonia, ulcerative colitis, or patients who should receive long-term glucocorticoid treatment (\\>10mg/d prednisone).\n5. With uncontrollable complications\n6. Inadequate organ function\n7. Known hypersensitivity reaction to any of the study drugs or components.\n\n9\\. Other unsuitable conditions determined by investigators.'}, 'identificationModule': {'nctId': 'NCT05013268', 'acronym': 'TiTanec', 'briefTitle': 'Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical Carcinoma', 'organization': {'class': 'OTHER', 'fullName': 'Ruijin Hospital'}, 'officialTitle': 'The Efficacy and Safety of Tislelizumab Combined With Taxanes and Platinum as Neoadjuvant Therapy for Patients With Local Advanced Cervical Carcinoma， an Open Lable，Single-center, Exploratory Clinical Trial', 'orgStudyIdInfo': {'id': 'TiTanec'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Tislelizumab plus TP regimen as neoadjuvant therapy for local advanced cervical carcinoma', 'description': 'Experimental:\n\nTislelizumab, paclitaxel/docetaxel, cisplatin/carboplatin The subjects enrolled in this trial will receive tislelizumab 200mg ivgtt d1, paclitaxel (175mg/m2 ivgtt d1) or docetaxel (75mg/m2 ivgtt d1), cisplatin (75mg/m2 ivgtt d1) or carboplatin (AUC=5 ivgtt d1). The regimen will be repeated every 3 weeks for 3 cycles. Chemotherapy regimen will be selected by investigators.\n\nSubjects will be enrolled serially.', 'interventionNames': ['Drug: Tislelizumab, paclitaxel/docetaxel, cisplatin/carboplatin']}], 'interventions': [{'name': 'Tislelizumab, paclitaxel/docetaxel, cisplatin/carboplatin', 'type': 'DRUG', 'description': '* Drug: Tislelizumab 200mg, d1, ivgtt, every 3 weeks, for 3 cycles\n* Drug: Paclitaxel; docetaxel Dose: 175mg/m2 d1; 75mg/m2 d1, every 3 weeks, for 3 cycles Other Name: none\n* Drug: Cisplatin; Carboplatin Dose: 75mg/m2 d1; AUC=5, d1, every 3 weeks, for 3 cycles Other Name: none', 'armGroupLabels': ['Tislelizumab plus TP regimen as neoadjuvant therapy for local advanced cervical carcinoma']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Shanghai', 'country': 'China', 'contacts': [{'name': 'Chenfei Zhou', 'role': 'CONTACT'}], 'facility': 'Ruijin Hospital, Shanghai JiaoTong University School of Medicine', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}], 'centralContacts': [{'name': 'Yan Shi', 'role': 'CONTACT', 'email': 'sy_rjh@aliyun.com', 'phone': '13810561979'}], 'overallOfficials': [{'name': 'Yan Shi', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Ruijin Hospital'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Ruijin Hospital', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Associate professor', 'investigatorFullName': 'Yan Shi', 'investigatorAffiliation': 'Ruijin Hospital'}}}}